Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016August 16, 2022 Alterity Therapeutics

Abstract from Movement Disorders Conference 2016

2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Prana Announces Successful Phase 2 Results in Huntington Disease Trial

February 18, 2014August 16, 2022

European Commission approves Orphan Designation for Alterity’s lead drug candidate

January 14, 2020August 16, 2022

Prana reports FY15 financial results

August 27, 2015August 16, 2022

Recent Posts

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065